众生药业(002317) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 615,880,806.76, representing a 58.07% increase compared to CNY 389,617,593.86 in the same period last year[9]. - Net profit attributable to shareholders was CNY 56,762,950.08, a 7.66% increase from CNY 52,725,870.58 year-on-year[9]. - The net profit after deducting non-recurring gains and losses surged by 110.41% to CNY 112,162,463.85 from CNY 53,305,854.10 in the previous year[9]. - The company achieved operating revenue of RMB 615.88 million in Q1 2021, a year-on-year increase of 58.07%[27]. - The net profit attributable to shareholders was RMB 56.76 million, representing a year-on-year increase of 7.66%[27]. - Total operating revenue for the current period reached CNY 615,880,806.76, a significant increase from CNY 389,617,593.86 in the previous period, reflecting a growth of approximately 58.2%[70]. - The company reported a net profit of CNY 1,135,056,885.71, up from CNY 1,078,750,472.25, reflecting a growth of approximately 5.2%[61]. - The net profit for the current period was CNY 54,847,857.32, compared to CNY 52,433,637.27 in the previous period, indicating a year-over-year increase of about 4.6%[80]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,001,649,527.67, an increase of 4.72% from CNY 4,776,078,558.12 at the end of the previous year[9]. - The company's total current assets as of March 31, 2021, were RMB 3,216,705,371.70, compared to RMB 3,133,308,420.62 at the end of 2020[52]. - Total assets increased to CNY 5,001,649,527.67, up from CNY 4,776,078,558.12, representing a growth of approximately 4.7%[58]. - Non-current assets totaled CNY 1,784,944,155.97, an increase from CNY 1,642,770,137.50, reflecting a growth of about 8.7%[58]. - Total liabilities increased to CNY 1,086,290,448.06 from CNY 1,069,161,727.99, showing a rise of approximately 1.6%[68]. - Total liabilities amounted to CNY 1,158,112,328.80 as of January 1, 2021, up from CNY 1,149,590,398.01 on December 31, 2020[106]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,249[12]. - The company’s minority shareholder equity increased by 88.17% to RMB 191.02 million, due to equity financing received by subsidiaries[27]. - The total equity attributable to shareholders rose to CNY 3,677,569,305.62 from CNY 3,524,977,152.62, an increase of about 4.3%[61]. - The total equity attributable to the parent company is approximately CNY 3.52 billion, showing a slight decrease of CNY 456,536.62 compared to the previous period[109]. Cash Flow - The net cash flow from operating activities decreased by 20.46% to CNY 50,198,713.06, down from CNY 63,112,731.12 in the same period last year[9]. - The company's cash and cash equivalents net increase was RMB 102.18 million, a decrease of 66.53% compared to the previous year[30]. - The ending cash and cash equivalents balance was CNY 1,424,560,370.34, up from CNY 1,125,152,391.67 in the previous period, representing an increase of approximately 26.6%[94]. - Cash inflow from financing activities was CNY 472,307,422.06, down from CNY 669,224,737.34 in the previous period, a decrease of approximately 29.5%[94]. - The net cash flow from financing activities was CNY 201,506,612.61, compared to CNY 274,336,983.10 in the previous period, indicating a decrease of about 26.5%[94]. Investment Activities - The company has completed the investment projects related to the purchase of equity in Xianqiang Pharmaceutical and the replenishment of working capital[41]. - The company has raised a total of RMB 999,999,988.00 from a non-public offering of 76,923,076 shares at RMB 13.00 per share, with a net amount of RMB 979,262,770.41 after deducting issuance costs[41]. - The investment progress of the small molecule chemical innovative drug cooperation project reached 87.70% as of the reporting period[44]. - The company reported a loss from investment income of CNY 193,804.67, contrasting with a gain of CNY 1,846,287.64 in the previous period[81]. Financial Strategy - The company plans to continue its "full product, full terminal, full channel" marketing strategy to drive future growth[27]. - The company has initiated a share repurchase plan to enhance investor confidence and stabilize stock prices[31]. - The company plans to repurchase shares using its own funds between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 14.00 per share, within a period of 6 months[35]. - The company has applied for a comprehensive credit line from banks not exceeding RMB 475 million to reduce financing risks and costs, with a one-year validity[35]. Research and Development - Research and development expenses increased to CNY 23,738,652.70 from CNY 21,274,023.90, reflecting a growth of approximately 11.6%[73]. - Research and development expenses increased to CNY 15,177,170.12 from CNY 13,301,218.52, showing a rise of approximately 14.1%[81]. Other Information - The company has not engaged in any securities or derivative investments during the reporting period[39][40]. - There were no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[38]. - The first quarter report has not been audited, which may affect the reliability of the financial data presented[117]. - The company maintains a consistent financial position with no significant adjustments in liabilities or assets reported[116].